GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Excelsior Biopharma Inc (ROCO:6496) » Definitions » Gross Margin %

Excelsior Biopharma (ROCO:6496) Gross Margin % : 44.19% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Excelsior Biopharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Excelsior Biopharma's Gross Profit for the three months ended in Mar. 2024 was NT$84.0 Mil. Excelsior Biopharma's Revenue for the three months ended in Mar. 2024 was NT$190.1 Mil. Therefore, Excelsior Biopharma's Gross Margin % for the quarter that ended in Mar. 2024 was 44.19%.


The historical rank and industry rank for Excelsior Biopharma's Gross Margin % or its related term are showing as below:

ROCO:6496' s Gross Margin % Range Over the Past 10 Years
Min: 21.48   Med: 35.61   Max: 42.75
Current: 41.71


During the past 12 years, the highest Gross Margin % of Excelsior Biopharma was 42.75%. The lowest was 21.48%. And the median was 35.61%.

ROCO:6496's Gross Margin % is ranked worse than
60.75% of 986 companies
in the Drug Manufacturers industry
Industry Median: 46.405 vs ROCO:6496: 41.71

Excelsior Biopharma had a gross margin of 44.19% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Excelsior Biopharma was 7.60% per year.


Excelsior Biopharma Gross Margin % Historical Data

The historical data trend for Excelsior Biopharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Excelsior Biopharma Gross Margin % Chart

Excelsior Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.96 21.48 21.92 42.75 39.78

Excelsior Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.30 35.15 40.51 46.42 44.19

Competitive Comparison of Excelsior Biopharma's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Excelsior Biopharma's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Excelsior Biopharma's Gross Margin % falls into.



Excelsior Biopharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Excelsior Biopharma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=306.9 / 771.562
=(Revenue - Cost of Goods Sold) / Revenue
=(771.562 - 464.632) / 771.562
=39.78 %

Excelsior Biopharma's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=84 / 190.111
=(Revenue - Cost of Goods Sold) / Revenue
=(190.111 - 106.102) / 190.111
=44.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Excelsior Biopharma  (ROCO:6496) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Excelsior Biopharma had a gross margin of 44.19% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Excelsior Biopharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of Excelsior Biopharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Excelsior Biopharma (ROCO:6496) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 14th Floor-6, Nangang District, Taipei, TWN, 11503
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, research of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.

Excelsior Biopharma (ROCO:6496) Headlines

No Headlines